The V599E BRAF mutation is uncommon in biliary tract cancers

Modern Pathology

Volumn 17, Issue 11, 2004, Pages 1386-1391

  Goldenberg, David ^a   Rosenbaum, Eli ^a   Argani, Pedram ^a   Wistuba, Ignacio I ^b   Sidransky, David ^a   Thuluvath, Paul J ^a   Hidalgo, Manuel ^a   Califano, Joseph ^a   Maitra, Anirban ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

BRAF; Cholangiocarcinoma; Gallbladder cancer; Gap ligase chain reaction; Mutector

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN;

ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BRAF GENE; CHILE; GALLBLADDER CANCER; GAP LIGASE CHAIN REACTION; GENE IDENTIFICATION; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER CANCER; MAJOR CLINICAL STUDY; MELANOMA; MUTATOR GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; SKIN CANCER; SOMATIC MUTATION; THYROID PAPILLARY CARCINOMA; UNITED STATES; V599E GENE;

BILIARY TRACT NEOPLASMS; HUMANS; LIGASE CHAIN REACTION; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 8144225290     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800204     Document Type: Article

References (31)

1. de Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N Engl J Med 1999;341:1368-1378.
2. Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transpl 2000;6:S30-S34.
3. Mansfield JC, Griffin SM, Wadehra V, et al. A prospective evaluation of cytology from biliary strictures. Gut 1997;40:671-677.
4. Sturm PD, Rauws EA, Hruban RH, et al. Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. Clin Cancer Res 1999;5:629-635.
5. Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000;95:204-207.
6. Bjornsson E, Kilander A, Olsson R. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 1999;19:501-508.
7. Muller P, Ostwald C, Puschel K, et al. Low frequency of p53 and ras mutations in bile of patients with hepatobiliary disease: a prospective study in more than 100 patients. Eur J Clin Invest 2001;31:240-247.
8. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
9. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22:6455-6457.
10. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63:4561-4567.
11. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003;90:378-381.
12. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40.
13. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-627.
14. Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2002;2:5-7.
15. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62:6451-6455.
16. Naoki K, Chen TH, Richards WG, et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002;62:7001-7003.
17. Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63:3883-3885.
18. Hingorani SR, Jacobetz MA, Robertson GP, et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-5202.
19. Cohen Y, Goldenberg-Cohen N, Parrella P, et al. Lack of BRAF mutafion in primary uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:2876-2878.
20. Singer G, Oldt III R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-486.
21. Abravaya K, Carrino JJ, Muldoon S, et al. Detection of point mutations with a modified ligase chain reaction (Gap-LCR). Nucleic Acids Res 1995;23:675-682.
22. Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52:706-712.
23. Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 2002;99:4265-4275.
24. Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromosomes Cancer 1991;3:1-7.
25. Taniai M, Higuchi H, Burgart LJ, et al. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002;123:1090-1098.
26. Ishimura N, Yamasawa K, Karim Rumi MA, et al. BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Lett 2003;199:169-173.
27. Calhoun ES, Jones JB, Ashfaq R, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003;163:1255-1260.
28. Kim IJ, Park JH, Kang HC, et al. Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet 2003;114:118-120.
29. Nagy A, Balint I, Kovacs G. Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors. Int J Cancer 2003;106:980-981.
30. Weber A, Langhanki L, Sommerer F, et al. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 2003;22:4757-4759.
31. Edmunds SC, Cree IA, Di Nicolantonio F, et al. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 2003;88:1403-1405.